Life-saving treatments
for patients with
advanced liver disease
Our company
We discover and develop life-saving treatments for patients with advanced liver disease at high risk of hospitalisation and death.
Our treatments are designed either to prevent or treat rare or life-threatening liver diseases.
We have a diverse late-stage pipeline including two medical devices and two therapeutic medicines for acute and chronic use.
Yaqrit is structured with four subsidiary companies to enable investment at the asset level or the parent company level. Please be in touch if you are interested to learn more.
Latest news
Yaqrit’s HE candidates set for phase 3 as company shows underpinning data at EASL
• Improved disease staging tool for hepatic encephalopathy, approved for use by FDA in phase 3 trials of IV ammonia scavenger (YAQ006)
• Dose-response data of oral ammonia scavenger (YAQ007) for prevention of HE recurrence
• In vivo demonstration of ammonia scavenger mechanism of action highlights potential synergistic combination with TLR-4 antagonist (YAQ005)
LONDON, May 7, 2025
• Dose-response data of oral ammonia scavenger (YAQ007) for prevention of HE recurrence
• In vivo demonstration of ammonia scavenger mechanism of action highlights potential synergistic combination with TLR-4 antagonist (YAQ005)
LONDON, May 7, 2025
READ MORE
Yaqrit showcases clinical progress at the European Association for the Study of the Liver (EASL) Congress, May 7-10th
• Shared data underpins key advanced trials in hepatic encephalopathy, acute-on-chronic liver failure (ACLF) and decompensated cirrhosis
• Management attending conference
LONDON, April 28, 2025
• Management attending conference
LONDON, April 28, 2025
READ MORE
Yaqrit secures NIHR grant for pivotal trials of its liver support device, DIALIVE, for patients with liver failure
• Trial to assess intensive care liver support system across 13 UK centers
• Rapid co-primary endpoints measured over 10 and 28 days; readout Q1 2027
• Aims to resolve life-threatening condition and impact survival
March 21, 2025
• Rapid co-primary endpoints measured over 10 and 28 days; readout Q1 2027
• Aims to resolve life-threatening condition and impact survival
March 21, 2025
READ MORE
Yaqrit strengthens board and senior management ahead of multi-prong clinical push in advanced liver disease
• Ex-Takeda VP Tauhid Ali, Ph.D., with broad leadership and drug development experience becomes Board Director
• Seasoned regulatory strategist Darren Rubin becomes VP, Amalive, heading development of the ammonia scavenger OPA, Yaqrit’s phase 3 treatment for hepatic encephalopathy
• Ex-J&J senior medtech director Sarah van Hellenberg Hubar-Fisher joins as VP Business Development leading commercial development of Yaqrit’s medical device assets
February 21, 2025
• Seasoned regulatory strategist Darren Rubin becomes VP, Amalive, heading development of the ammonia scavenger OPA, Yaqrit’s phase 3 treatment for hepatic encephalopathy
• Ex-J&J senior medtech director Sarah van Hellenberg Hubar-Fisher joins as VP Business Development leading commercial development of Yaqrit’s medical device assets
February 21, 2025
READ MORE
Yaqrit prepares phase 3 for ammonia scavenger in hepatic encephalopathy
• Acute and chronic treatment for hepatic encephalopathy acquired from Mallinckrodt Pharmaceuticals in September 2024
• Extended pre-clinical, clinical and IP package includes FDA and EMA orphan drug and FDA fast track designations
February 11, 2025
• Extended pre-clinical, clinical and IP package includes FDA and EMA orphan drug and FDA fast track designations
February 11, 2025
READ MORE
Yaqrit appoints new CEO Troels Jordansen to implement late clinical development and commercial strategy
• Experienced private and public listed CEO
• Successful fund raising and business development track record
London, UK: January 10, 2025
• Successful fund raising and business development track record
London, UK: January 10, 2025
READ MORE
CARBALIVE beads help restore healthy gut microbiome and reduce liver disease progression
Tiny beads of carbon could potentially transform the way we treat a range of disease.
April 15, 2024
April 15, 2024
READ MORE
DIALIVE Liver Dialysis Device Shows Promise in First Clinical Trial for ACLF
Excited to share out ground breaking Liver Research has been published.
June 1, 2023
June 1, 2023
READ MORE
Contact us
Troels Jordansen, Chief Executive Officer
Troels@Yaqrit.com
+31 6 1834 5326
Registered address: 34 High Street, Aldridge, Walsall, WS9 8LZ